The clinical utility of the calcitonin gene–related peptide (CGRP) receptor antagonist ubrogepant may extend beyond the treatment of acute migraine to alleviating common prodromal symptoms of migraine ...

BARCELONA — For the first time, new research shows that taking a specific class of migraine medication during the prodromal phase reduces the development and severity of the subsequent headache. In ...

Please provide your email address to receive an email when new articles are posted on . Participants with word-finding issues reported concentration trouble, and vice versa. No cognitive performance ...

The researchers found that after treatment of qualifying prodrome events, participants after ubrogepant treatment had a significantly greater ability to function normally over 24 hours than those ...

A migraine drug called ubrogepant doesn't just reduce the severity of a migraine attack – it also dials down the non-headache symptoms in the prodrome: the hours leading up to the main event. That's ...

If you have migraine, you probably know the signs of an attack all too well: A throbbing headache, nausea, and sensitivity to certain lights and sounds can be hell. But you might also notice that you ...

Treatment with oral ubrogepant (Ubrelvy) during the migraine prodrome led to more patients being able to function normally, a prespecified secondary endpoint analysis of the phase III PRODROME trial ...

Please provide your email address to receive an email when new articles are posted on . The study included 518 adults aged 18 to 75 years with at least a 1-year history of migraine. Adverse events ...

Migraine is a common condition, and migraine attacks are events that often involve severe headache pain that inhibits a person’s ability to go about everyday activities. Attacks can be challenging to ...

Absence of photophobia at 2 hours postdose occurred in 19.5 and 12.5% of ubrogepant- and placebo-treated events, respectively. HealthDay News — Ubrogepant during the prodromal phase of migraine may ...